But despite clinical implementation of these improved inhibitors of AR signaling, response is partial and temporal and tumors inevitably progress into a more aggressive and typically lethal form of prostate cancer (Antonarakis et al, 2014). The gene discussed is AR; the disease is Familial prostate cancer.